Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
2.880
-0.040 (-1.37%)
At close: May 28, 2025, 4:00 PM
2.900
+0.020 (0.68%)
After-hours: May 28, 2025, 5:26 PM EDT
Akebia Therapeutics Employees
Akebia Therapeutics had 181 employees as of December 31, 2024. The number of employees increased by 14 or 8.38% compared to the previous year.
Employees
181
Change (1Y)
14
Growth (1Y)
8.38%
Revenue / Employee
$1,021,597
Profits / Employee
-$250,348
Market Cap
756.39M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
AKBA News
- 10 hours ago - Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025 - GlobeNewsWire
- 1 day ago - Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025 - GlobeNewsWire
- 15 days ago - Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference - GlobeNewsWire
- 20 days ago - Akebia Therapeutics, Inc. (AKBA) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 20 days ago - Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 27 days ago - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 27 days ago - Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights - GlobeNewsWire
- 7 weeks ago - Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa - GlobeNewsWire